Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dMIP3α-gp100
- Development stage
- Preclinical
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intramuscular (via In Vivo Electroporation In Animal Studies)
01
Overview
dMIP3α-gp100 is an experimental DNA vaccine composed of a fusion between the chemokine MIP3α (also known as CCL20) and the melanoma-associated antigen gp100. This construct is designed to target and deliver the gp100 tumor antigen directly to immature dendritic cells via the MIP3α component, which binds to CCR6 on dendritic cells, thereby enhancing antigen presentation and the subsequent T-cell immune response. Preclinical studies in the B16F10 mouse melanoma model show that this chemokine-antigen fusion vaccine enhances immunogenicity, increases vaccine-specific CD8+ tumor-infiltrating lymphocytes, and improves survival compared to antigen-only approaches. The vaccine platform is modular and potentially adaptable for various antigens and indications, notably for therapeutic cancer vaccines and neoantigen personalized therapies[1][7].
- Other names
- MIP3α-gp100MIP3alpha-gp100MIP-3alpha-gp100MIP 3alpha-gp100CCL20-gp100CCL-20-gp100CCL 20-gp100
02
Targets
CCR6 (C-C motif chemokine receptor 6)PMEL (Melanocyte Protein PMEL)
Beyond the preview
Go deeper on dMIP3α-gp100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dMIP3α-gp100.